Administrative bulletin: 2026-05-001 Updates and new information


Date: May 1, 2026

Topics covered in this administrative bulletin are applicable to:

Professional and facility Providers

Unless otherwise noted, if you have any questions regarding the information in this bulletin, please contact your Provider Engagement Consultant or visit capbluecross.com/wps/portal/cap/provider/pec-look-up and enter your NPI or Tax ID to identify your designated point of contact at Capital Blue Cross.

Professional and facility Providers


Independent laboratory network expansion and changes

  • CHIP
  • EPO
  • FEP PPO
  • HMO
  • Medicare Advantage HMO
  • POS
  • PPO
  • Traditional and Comprehensive
  • Medicare Advantage PPO

KEY POINT: Capital Blue Cross and its affiliates (Capital) have started direct contract negotiations with independent laboratory providers across all lines of business1 for services rendered on or after July 1, 2026. This replaces prior arrangements managed by Avalon Client Services, LLC (Avalon).

As of June 30, 2026, Capital will no longer utilize Avalon’s laboratory network for laboratory services.

Becoming a participating laboratory

Independent laboratories interested in participating with Capital Blue Cross should visit our join our network page for additional information and enrollment instructions.

Adoption of EviCore medical policies

Beginning July 1, 2026, Capital Blue Cross will adopt Evicore’s medical policies for laboratory services (replacing Avalon).

All providers will be required to comply with the medical policy criteria outlined in these policies. This requirement applies to outpatient laboratory services across all provider types, including:

  • Independent laboratories.
  • Physician's office laboratories.
  • Hospital-based laboratories.

Providers are reminded of the importance of verifying member eligibility and benefits prior to rendering services.

Medical policy enforcement

Medical policy enforcement will occur during claims adjudication. Laboratory services that do not meet applicable coverage criteria will be considered non-covered by Capital Blue Cross.

Accessing EviCore clinical guidelines and CPT codes

Providers and office staff are encouraged to review EviCore’s clinical guidelines and associated CPT codes to ensure accurate billing and appropriate utilization.

A link to EviCore’s Clinical Guidelines is available on Capital’s medical policies page.

Disclaimer: Capital Blue Cross contracts with eviCore healthcare (EviCore), an independent company, to review requests for certain services for medical necessity and appropriateness.


1Providers must participate with Traditional Medicare in order to participate in Capital Blue Cross Medicare Advantage products.


EviCore - Clinical Guidelines for Lab Management Program, version 2.0.2026

  • CHIP
  • EPO
  • FEP PPO
  • HMO
  • Medicare Advantage HMO
  • POS
  • PPO
  • Traditional and Comprehensive
  • Medicare Advantage PPO

KEY POINT: Effective July 1, 2026, EviCore will implement Clinical Guidelines for Lab Management Program, version 2.0.2026, for both utilization management and medical policy enforcement through claims editing.

Currently, EviCore serves as Capital’s delegated utilization management vendor for the Molecular Lab Preauthorization Program. Beginning July 1, 2026, Capital will expand this partnership to include medical policy enforcement through claims editing for non-molecular laboratory services and select molecular laboratory services that are not subject to preauthorization. Additional details are available in the article titled Independent Laboratory Network Expansion and Changes.

EviCore's Clinical Guidelines for Lab Management Program, version 2.0.2026, along with the delegated list of services, has been reviewed and approved by Capital Utilization Management committees for implementation effective July 1, 2026. This comprehensive policy manual outlines the clinical criteria that will be applied in both utilization management determinations and medical policy enforcement for Capital members.

The Clinical Guidelines for Lab Management Program have been revised from the prior version as follows.

Clinical Guidelines for Lab Management Program, version 2.0.2026

New clinical guidelines, effective July 1, 2026
  • Allergy Laboratory Testing (MOL.CS.317.X)
  • Celiac Disease Testing (MOL.CS.319.X)
  • Chromosome Analysis for Reproductive Disorders, Prenatal Testing, and Developmental Disorders (MOL.CS.289.A)
  • Cognitive Impairment Biomarkers (MOL.CS.400.X)
  • Cologuard Plus Screening for Colorectal Cancer (MOL.CS.422.A)
  • Drug Testing (MOL.CS.315.X)
  • Flow Cytometry (MOL.CS.103.A)
  • Gastrointestinal Pathogen Panel GIPP Molecular Testing (MOL.CS.277.A)
  • Helicobacter pylori Laboratory Testing (MOL.CS.318.A)
  • Hereditary Cancer Syndrome Genetic Testing (MOL.TS.436.A)
  • Human Immunodeficiency Virus Laboratory Testing (MOL.CS.321.X)
  • Human Papillomavirus HPV Molecular Testing (MOL.CS.362.A)
  • Immunohistochemistry IHC (MOL.CS.104.A)
  • Inflammatory Biomarkers (MOL.CS.420.X)
  • Inflammatory Bowel Disease Biomarker Testing (MOL.CS.359.X)
  • Infectious Disease Laboratory Testing (MOL.CU.398.X)
  • Insulin and Related Peptides (MOL.CS.423.X)
  • Liver Fibrosis Assessment Biomarkers (MOL.CS.401.X)
  • Lyme Disease Testing (MOL.CS.332.X)
  • Metabolic Testing (MOL.CS.418.X)
  • Mineral Testing (MOL.CS.417.X)
  • Nail Disorder Infectious Disease Testing, Including Onychomycosis (MOL.CS.402.X)
  • Non-Molecular Biomarkers in Oncology (MOL.CS.374.X)
  • Obsolete Tests (MOL.CS.322.X)
  • Pancreatitis Laboratory Testing (MOL.CS.404.X)
  • Parathyroid Hormone Testing (MOL.CS.390.X)
  • Pathology Testing with Mohs Micrographic Surgery (MOL.CS.363.A)
  • Prenatal Aneuploidy FISH Testing (MOL.CS.218.A)
  • Prenatal Maternal Serum Screening (MOL.CS.220.X)
  • Prostate Specific Antigen Testing (MOL.CS.373.X)
  • Reproductive Hormone Testing in Adults (MOL.CS.408.X)
  • Respiratory Infection Pathogen Panel RIPP Molecular Testing (MOL.CS.293.A)
  • Rheumatoid Arthritis Laboratory Testing (MOL.CS.369.X)
  • Sexually Transmitted and Other Reproductive Tract Infection Testing (MOL.CS.106.A)
  • Special Histochemical Stains (MOL.CS.409.X)
  • Testosterone Testing (MOL.CS.376.X)
  • Thyroid Disorder Laboratory Testing (MOL.CS.320.X)
  • UroVysion FISH for Bladder Cancer (MOL.CS.108.A)
  • Urinary Tract Infection Molecular Testing (MOL.CS.403.A)
  • Vitamin B12 and Folate Deficiency Testing (MOL.CS.426.X)
  • Vitamin D Testing (MOL.CS.331.X)
  • Vitamin Testing (MOL.CS.416.X)
Retired clinical guidelines, effective July 1, 2026
  • Ashkenazi Jewish Carrier Screening (MOL.TS.129.A)
  • BRCA Analysis (MOL.TS.238.A)
  • Familial Adenomatous Polyposis Genetic Testing (MOL.TS.168.A)
  • Hereditary Cancer Syndrome Multigene Panels (MOL.TS.182.A)
  • Li-Fraumeni Syndrome Genetic Testing (MOL.TS.193.A)
  • Lynch Syndrome Genetic Testing (MOL.TS.197.A)
  • Multiple Endocrine Neoplasia Type 1 Genetic Testing (MOL.TS.285.A)
  • Multiple Endocrine Neoplasia Type 2 Genetic Testing (MOL.TS.286.A)
  • MUTYH-Associated Polyposis Genetic Testing (MOL.TS.206.A)
  • NETest (MOL.TS.250.A)
  • PALB2 Genetic Testing for Cancer Risk (MOL.TS.251.A)
  • Peutz-Jeghers Syndrome Genetic Testing (MOL.TS.216.A)
  • Von Hippel-Lindau Disease Genetic (MOL.TS.233.A)
Substantive criteria updates for clinical guidelines, effective July 1, 2026
  • Amyotrophic Lateral Sclerosis (ALS) Genetic Testing (MOL.TS.125.A)
  • BCR-ABL Negative Myeloproliferative Neoplasm Testing (MOL.TS.240.A)
  • Cardiomyopathy and Arrhythmia Genetic Testing (MOL.TS.410.A)
  • Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and Expanded (MOL.TS.165.A)
  • Charcot-Marie-Tooth Neuropathy Genetic Testing (MOL.TS.148.A)
  • Early Onset Familial Alzheimer Disease Genetic Testing (MOL.TS.162.A)
  • Epilepsy Genetic Testing (MOL.TS.257.A)
  • Experimental, Investigational, or Unproven Laboratory Testing (MOL.CU.117.X)
  • Familial Hypercholesterolemia Genetic Testing (MOL.TS.169.A)
  • Hereditary Ataxia Genetic Testing (MOL.TS.425.A)
  • Hereditary Connective Tissue and Thoracic Aortic Disease Genetic Testing (MOL.TS.425.A)
  • Hereditary Pancreatitis Genetic Testing (MOL.TS.287.A)
  • Inherited Bone Marrow Failure Syndrome (IBMFS) Testing (MOL.TS.360.A)
  • Laboratory Billing and Reimbursement (MOL.AD.412.X)
  • Limb-Girdle Muscular Dystrophy Genetic Testing (MOL.TS.288.A)
  • Liquid Biopsy Testing (MOL.TS.194.A)
  • Mammaprint 70-Gene Breast Cancer Recurrence Assay (MOL.TS.200.A)
  • Maturity-Onset Diabetes of the Young (MODY) Genetic Testing (MOL.TS.258.A)
  • Mitochondrial Disorders Genetic Testing (MOL.TS.266.A)
  • Noonan Spectrum Disorder Genetic Testing (MOL.TS.371.A)
  • Nonsyndromic Hearing Loss and Deafness Genetic Testing (MOL.TS.273.A)
  • Oncotype DX for Breast Cancer Prognosis (MOL.TS.211.A)
  • Pharmacogenomic Testing for Drug Toxicity and Response (MOL.CU.118.A)
  • Primary Ciliary Dyskinesia Genetic Testing (MOL.TS.419.A)
  • Somatic Mutation Testing (MOL.TS.230.A)
Non-Substantive criteria updates for clinical guidelines, effective July 1, 2026
  • Afirma Thyroid Cancer Classifier Tests (MOL.TS.122.A)
  • AlloMap Gene Expression Profiling For Heart Transplant Rejection (MOL.TS.123.A)
  • Autism, Intellectual Disability, and Developmental Delay Genetic Testing (MOL.TS.269.A)
  • Chromosomal Microarray Testing For Developmental Disorders (Prenatal and Postnatal) (MOL.TS.150.A)
  • Cologuard Screening for Colorectal Cancer (MOL.TS.152.A)
  • Decipher Prostate Cancer Classifier (MOL.TS.294.A)
  • Exome Sequencing (MOL.TS.235.A)
  • Familial Malignant Melanoma Genetic Testing (MOL.TS.170.A)
  • Genetic Testing by Multigene Panels (MOL.CU.116.A)
  • Genome Sequencing (MOL.TS.306.A)
  • Hereditary (Germline) Testing After Tumor (Somatic) Testing (MOL.CU.246.A)
  • HFE Hemochromatosis Genetic Testing (MOL.TS.183.A)
  • Human Platelet and Red Blood Cell Antigen Genotyping (MOL.TS.361.A)
  • Inherited Thrombophilia Genetic Testing (MOL.TS.370.A)
  • Non-Invasive Prenatal Screening (MOL.TS.209.A)
  • OvaSuite (MOL.TS.366.X)
  • PCA3 Testing for Prostate Cancer (MOL.TS.215.A)
  • PTEN Hamartoma Tumor Syndromes Genetic Testing (MOL.TS.223.A)
  • Special Circumstances Influencing Coverage Determinations (MOL.AD.364.A)
  • ThyGeNEXT and ThyraMIR miRNA Gene Expression Classifier (MOL.TS.259.A)
  • Thyroseq (MOL.TS.270.A)

To preview EviCore’s Clinical Guidelines for Lab Management Program, Version 2.0.2026, select Future, and Capital Blue Cross Lab Management Guidelines Effective 07/01/2026-12/31/2026.

A complete list of CPT/HCPCS codes requiring preauthorization can be found on Capital's single source preauthorization list.

Disclaimer: Capital Blue Cross contracts with eviCore healthcare (EviCore), an independent company, to review requests for certain services for medical necessity and appropriateness.


New Reimbursement Policy NR-09.008 – Preventive Medicine Visit with E/M

  • CHIP
  • EPO
  • FEP PPO
  • HMO
  • Medicare Advantage HMO
  • POS
  • PPO
  • Traditional and Comprehensive
  • Medicare Advantage PPO

KEY POINT: Effective July 1, 2026, Capital will introduce Reimbursement Policy NR-09.008 – Preventive Medicine Visit with E/M.

The new policy establishes guidelines for a problem-oriented evaluation and management (E/M) visit billed on the same date of service as a preventive medicine visit, annual wellness visit, or “Welcome to Medicare” visit.

Capital Blue Cross permits reimbursement for both services when modifier 25 is appended to a separately identifiable problem-oriented E/M visit furnished by the same physician or qualified health care professional on the same date of service.

Under these circumstances, the preventive or wellness visit will be reimbursed at 100 percent of the contracted allowable rate, and the problem-oriented E/M visit will be reimbursed at 50 percent.